T-cell immunotherapies and flow cytometry

Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.

Flow cytometry and the development of immuno-oncology therapies

The use of flow cytometry is a staple within many immuno-oncology companies, as it is a very well established and reliable method of generating multiparametric data from different cell types, including peripheral blood and its components, bone marrow and some tumour types. Understanding the phenotypic profile of immune cell subsets at the single-cell level, by detecting their characteristic surface proteins, is key for the development of therapeutics in this area and flow cytometry is the ideal technique for doing this. Furthermore, it has also expanded into the area of functional biology, providing a readout of cytotoxic assays, intracellular cytokine staining and proliferation assays. Therefore, flow cytometry continues to be a powerful and flexible tool for understanding our cells and technical developments in the area continue.